Petros Pharmaceuticals
PTPI
PTPI was delisted on the 21st of May, 2025.
12 hedge funds and large institutions have $165K invested in Petros Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
9% more funds holding
Funds holding: 11 → 12 (+1)
0.02% more ownership
Funds ownership: 0.19% → 0.21% (+0.02%)
3% less capital invested
Capital invested by funds: $171K → $165K (-$5.83K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$35.5K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$9.41K |
| 3 |
BlackRock
New York
|
+$143 |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$36 |
| 5 |
Morgan Stanley
New York
|
+$36 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$23.7K |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$143 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $44.9K | – | – | – |
|
|
VF
2
Virtu Financial
New York
| $35K | +$35.5K | +993 | New |
|
|
SSA
3
Schonfeld Strategic Advisors
New York
| $31.9K | -$143 | -4 | -0.4% |
|
|
4
BlackRock
New York
| $23.4K | +$143 | +4 | +0.6% |
|
5
Geode Capital Management
Boston,
Massachusetts
| $14.9K | – | – | – |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $12.9K | +$9.41K | +263 | +258% |
|
|
EL
7
EMFO LLC
Weston,
Florida
| $1.41K | – | – | – |
|
|
NFSG
8
Newbridge Financial Services Group
Boca Raton,
Florida
| $169 | – | – | – |
|
9
Group One Trading
Chicago,
Illinois
| $112 | – | – | – |
|
|
10
Morgan Stanley
New York
| $54 | +$36 | +1 | +100% |
|
|
11
Fidelity Investments
Boston,
Massachusetts
| $28 | +$36 | +1 | New |
|
12
Osaic Holdings
Scottsdale,
Arizona
| $20 | – | – | – |
|
13
Wells Fargo
San Francisco,
California
| $17 | – | – | – |
|
14
1832 Asset Management
Toronto,
Ontario, Canada
| $14 | – | – | – |
|
15
First Manhattan
New York
| $14 | – | – | – |
|
16
Bank of America
Charlotte,
North Carolina
| $1 | – | – | – |
|
|
17
Citadel Advisors
Miami,
Florida
| – | -$23.7K | -572 | Closed |
|
PTPI Hedge Fund Activity: Q4 2023 in Review
12 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Petros Pharmaceuticals (PTPI) for Q4 2023, worth a combined $165K — down 3.4% from $171K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new PTPI positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $35.5K. The largest seller was Citadel Advisors, exiting entirely with an estimated $23.7K sold.
- 12 institutional investors held Petros Pharmaceuticals (PTPI) as of Q4 2023, up from 11 in Q3 2023.
- Funds reported $165K of Petros Pharmaceuticals stock for Q4 2023, down 3.4% quarter-over-quarter.
- 2 funds opened new Petros Pharmaceuticals positions in Q4 2023 and 1 closed out, a net change of +1 holder.
- The largest Petros Pharmaceuticals buyer in Q4 2023 was Virtu Financial, an estimated $35.5K added.
- The largest Petros Pharmaceuticals seller in Q4 2023 was Citadel Advisors, an estimated $23.7K sold.
Based on aggregated 13F filings for Q4 2023.